Clinical trial
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric…
NCT03329690 · Daiichi Sankyo Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT03329690 |
|---|---|
| Title | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01] |
| Official title | A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
| Lead sponsor | Daiichi Sankyo Co., Ltd., Industry |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasm, Gastrointestinal |
| Intervention type | Drug |
| Interventions | DS-8201a, Physician's Choice |
| Enrollment | 233 |
| Start date | Nov 2, 2017 |
| Primary completion | Nov 8, 2019 |
| Completion | Dec 11, 2020 |
| First posted | Nov 6, 2017 |
| Last update posted | Mar 18, 2022 |
| Countries | Japan, South Korea |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: